Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Abroad (travel likely)RecruitingPHASE2
Conditions
Suicide · Depressive Disorder, Treatment-Resistant · Ketamine · Molecular Mechanisms of Pharmacological Action · Neurotransmitter Agents · Excitatory Amino Acid Agents · Physiological Effects of Drugs · Depressive Disorder, Major · Depressive Disorder · Depression · Mental Disorders · Mood Disorders · Behavioral Symptoms
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (NIH Clinical Center Office of Patient Recruitment (OPR) · ccopr@nih.gov · 800-411-1222
Study leads
Carlos A Zarate, M.D.
Principal Investigator
National Institute of Mental Health (NIMH)